HMA

Cecilia BrownMyelodysplastic Syndromes | November 16, 2022
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
Read More
Cecilia BrownMyelodysplastic Syndromes | November 16, 2022
It led to an overall response rate of 74% in patients with newly diagnosed IDH2-mutated myelodysplastic syndrome.
Leah SherwoodMyelodysplastic Syndromes | November 16, 2022
The researchers analyzed data from previously untreated adult patients with low- or intermediate-risk MDS.
Advertisement
Leah SherwoodMyelodysplastic Syndromes | February 2, 2023
A retrospective study showed that response rate and survival outcome are still modest for high-risk patients.
Advertisement
Advertisement
Advertisement
Editorial Board